drugset / Trial / NCT02556606
Ketamine for Treatment Resistant Late-Life Depression
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to examine the effectiveness of a single infusion of ketamine (KET), to determine which dose is optimal 7 days after infusion using Bayesian Adaptive Randomization, and to learn about how ketamine works in the body and brain in persons with late-life treatment resistant depression.
Timeline
- Start
- 2015-10-01
- Primary completion
- 2020-03-31
- Completion
- 2020-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketamine | Small molecule | 0.1 mg/kg | Intravenous |
| Subject | Ketamine | Small molecule | 0.25 mg/kg | Intravenous |
| Subject | Ketamine | Small molecule | 0.5 mg/kg | Intravenous |
| Comparator | Midazolam | Small molecule | 0.03 mg/kg | Intravenous |